| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Shenzhen Chipscreen Biosciences Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥20.45 |
| 52 Week High | CN¥30.50 |
| 52 Week Low | CN¥12.47 |
| Beta | 0.55 |
| 1 Month Change | 15.15% |
| 3 Month Change | 10.18% |
| 1 Year Change | -31.44% |
| 3 Year Change | -45.04% |
| 5 Year Change | n/a |
| Change since IPO | -78.54% |
Recent News & Updates
Shareholder Returns
| 688321 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -1.6% | -0.7% | -0.2% |
| 1Y | -31.4% | -15.9% | -17.8% |
Return vs Industry: 688321 underperformed the CN Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 688321 underperformed the CN Market which returned -17.8% over the past year.
Price Volatility
| 688321 volatility | |
|---|---|
| 688321 Average Weekly Movement | 9.0% |
| Pharmaceuticals Industry Average Movement | 7.9% |
| Market Average Movement | 8.9% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.4% |
Stable Share Price: 688321's share price has been volatile over the past 3 months.
Volatility Over Time: 688321's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,057 | Xian-Ping Lu | www.chipscreen.com |
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research, development, and sale of original small molecule drugs. The company develops precursor compounds and original new drug product lines for the treatment of human diseases in five therapeutic areas, including cancer, metabolic diseases, autoimmune disorders, central nervous system disorders, and antivirals. It is developing chidamide, a subtype-selective benzamide inhibitor of histone deacetylase (HDAC) primarily targeting subtypes 1, 2, 3 of class I HDAC; chiglitazar, a new-generation insulin sensitizing candidate drug for the treatment of type 2 diabetes mellitus; chiauranib, an aurora B/VEGFR/PDGFR /c-Kit/CSF1R inhibitor; and CS12192, a highly selective JAK3 kinase inhibitor.
Shenzhen Chipscreen Biosciences Co., Ltd. Fundamentals Summary
| 688321 fundamental statistics | |
|---|---|
| Market cap | CN¥8.10b |
| Earnings (TTM) | CN¥88.84m |
| Revenue (TTM) | CN¥523.71m |
93.8x
P/E Ratio15.9x
P/S RatioIs 688321 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688321 income statement (TTM) | |
|---|---|
| Revenue | CN¥523.71m |
| Cost of Revenue | CN¥56.97m |
| Gross Profit | CN¥466.74m |
| Other Expenses | CN¥377.90m |
| Earnings | CN¥88.84m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 29, 2024
| Earnings per share (EPS) | 0.22 |
| Gross Margin | 89.12% |
| Net Profit Margin | 16.96% |
| Debt/Equity Ratio | 62.3% |
How did 688321 perform over the long term?
See historical performance and comparison